文献速递白血病

RUNX1突变急性髓系白血病患者一线治疗方案对预后影响的差异

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2022-09-26

该回顾性研究分析了907例新诊断急性髓系白血病(AML)患者(含137例RUNX1突变型),接受强化化疗(IC)、不含维奈克拉的低强度治疗(LIT without VEN)或含维奈克拉的低强度治疗(LIT with VEN)。按RUNX1状态分层,无论接受何种治疗,RUNX1突变型与野生型AML的结局均无统计学显著差异。在无其他不良风险细胞分子特征的患者中,RUNX1突变型接受IC或LIT without VEN时总生存期(OS)较差,但接受LIT with VEN时则无此差异。

要点

  • 按RUNX1状态分层,RUNX1突变型与野生型AML的结局无统计学显著差异,与治疗无关。
  • 在无其他不良风险特征患者中,RUNX1突变型接受IC或LIT without VEN时OS较差。
  • 接受LIT with VEN时,RUNX1突变型与野生型AML的OS无统计学显著差异。

核心结论

  • RUNX1突变型AML的预后影响可能取决于治疗方案,使用含维奈克拉方案时RUNX1突变可能不影响临床结局。

研究设计与样本

  • 回顾性分析907例新诊断AML患者,其中137例为RUNX1突变型AML,接受一线IC、LIT without VEN或LIT with VEN治疗。

主要发现

  • 按RUNX1状态分层,RUNX1突变型与野生型AML的结局无统计学显著差异,与所接受治疗无关。
  • 接受LIT with VEN的患者中,RUNX1突变型较野生型总生存期(OS)有更优趋势(中位OS 25.1个月 vs 11.3个月;2年OS率54% vs 33%;p=0.12)。
  • 在无其他不良风险细胞分子特征的患者中,RUNX1突变型接受IC者OS较差(p=0.02),接受LIT without VEN者OS较差(p=0.003)。
  • 在无其他不良风险细胞分子特征的患者中,接受LIT with VEN者RUNX1突变型与野生型OS无统计学显著差异(25.1个月 vs 30.0个月;2年OS率59% vs 54%;p=0.86)。
  • 多因素分析显示RUNX1突变状态与治疗之间可能存在交互作用,提示接受IC与LIT with VEN时RUNX1突变的预后影响不同。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RUNX1-mutated (mRUNX1) acute myeloid leukemia (AML) has historically been associated with poor outcomes in the setting of conventional chemotherapy. The prognostic impact of mRUNX1 AML is not well-established in the current era of lower-intensity treatment regimens incorporating venetoclax. We retrospectively analyzed 907 patients with newly diagnosed AML, including 137 patients with mRUNX1 AML, who underwent first-line therapy with intensive chemotherapy (IC), low-intensity therapy without venetoclax (LIT without VEN), or LIT with VEN. When stratified by RUNX1 status, there was no statistically significant difference in outcomes between mRUNX1 and wild-type (wtRUNX1) AML, regardless of therapy received. However, among patients who received LIT with VEN, there was a trend towards superior overall survival (OS) in those with mRUNX1 AML (median OS for mRUNX1 vs. wtRUNX1: 25.1 vs. 11.3 months; 2-year OS 54% vs. 33%; p = 0.12). In patients without another adverse-risk cyto-molecular feature, the presence of mRUNX1 conferred inferior OS in patients who received IC (p = 0.02) or LIT without VEN (p = 0.003) but not in those who received LIT with VEN (mRUNX1 vs. wtRUNX1: 25.1 vs. 30.0 months; 2-year OS 59% vs. 54%; p = 0.86). A multivariate analysis showed possible interaction between RUNX1 mutation status and treatment, suggesting a differential prognostic impact of RUNX1 mutations when patients received IC versus LIT with VEN. In summary, the prognostic impact of mRUNX1 AML may be treatment-dependent, and the presence of RUNX1 mutations may not impact clinical outcomes when venetoclax-based regimens are used.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Venugopal S, DiNardo CD, Loghavi S, et al. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022. PMID: 36087091. doi:10.1002/ajh.26724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。